OutSystems Platform supports fast roll-out of US Biotech
Redwood City - CA - 02 May 2006
OutSystems announces that Tercica Inc., a US based biopharmaceutical company, has created an efficient, easy to use and user-friendly CRM system in just ten weeks using OutSystems Platform.
The TerciTalk system manages the company’s interaction with all of its customers, including payers, physicians and other relevant medical personnel. The system offers full traceability of all actions taken by users and can be accessed through mobile interfaces that make the system fully available to the sales team via blackberry.
Despite being highly customized, the whole system was created and deployed in just ten weeks. The flexibility provided by OutSystems Platform was key to support such level of customization and to ensure user feedback was constantly reflected in the system's functionalities.
“We are a small biotech company, yet with the advent of our first product approval, we needed a cost-effective CRM system fully tailored to our specific needs that is state of the art and extremely easy to use for our commercial organization. OutSystems Platform has provided a system that is as efficient and easy to use for our end-users as any CRM that I have been involved with in my 20+ year career in this industry,“ says Chris Rivera, Tercica’s Senior Vice-President of Commercial Operations.
TerciTalk is one of the systems already in production created with OutSystems Platform. Tercica has created several systems, including an eTime-Off application for Human Resources, and will continue to develop its software factory to support other company processes. As Bill Yates, Tercica’s Vice-President, IT points out, “While working on this project, we deployed a number of other applications built with OutSystems technology, taking full advantage of its quick time-to-market.”
The agility provided by OutSystems Platform was fundamental for Tercica’s choice. According to Paulo Rosado, OutSystems CEO, “The OutSystems value proposition of Build Fast, Change Faster and Operate Cheaper resonates easily with today’s US enterprise, especially in fast growing industries like Biotech. These organizations need tailored IT solutions that can be delivered in weeks and not in months or years. And they need the assurance that these solutions are flexible enough to quickly accommodate the evolution of the business.”
Tercica, Inc. is a biopharmaceutical company focused on the development and commercialization of products to improve endocrine health. The company's first product, Increlex(TM) (mecasermin (rDNA origin) injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the long-term treatment of severe Primary IGFD. For further information on Tercica, please visit www.tercica.com